Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Circulating Biomarkers Clear all
Terminated Phase 4 Interventional Results available

Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes

NCT05139914
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Endothelial Dysfunction
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
30 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jun 25, 2026, 11:03 PM EDT
Active, not recruiting Phase 2 Interventional

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964
View directory record Official record
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 25, 2026, 11:03 PM EDT
Recruiting No phase listed Observational

Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study

NCT07196839
View directory record Official record
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 25, 2026, 11:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Healthy Human Control Blood Collection for Validation of Biomarker Assay

NCT02302885
View directory record Official record
Conditions
Healthy
Interventions
Blood collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jun 25, 2026, 11:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers to Predict CRT Response in Patients With HF (BIOCRT)

NCT01949246
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2022 · Synced Jun 25, 2026, 11:03 PM EDT
Not listed Early Phase 1 Interventional

Assessing Bioavailability of CoQ10 Supplementation in Burn Patients

NCT02251626
View directory record Official record
Conditions
Burn Injury
Interventions
coenzyme Q10, Placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jun 25, 2026, 11:03 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

NCT04068103
View directory record Official record
Conditions
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
Interventions
Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Patient Observation
Drug · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
932
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 639 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Jun 25, 2026, 11:03 PM EDT
Recruiting No phase listed Observational

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors

NCT05480644
View directory record Official record
Conditions
Brain Tumor, Primary, Brain Metastases, Adult
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jun 25, 2026, 11:03 PM EDT
Recruiting No phase listed Observational

Tempus Small Cell Lung Cancer Observational Study (Sculptor)

NCT05257551
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Los Alamitos, California • Aurora, Colorado • Peoria, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 25, 2026, 11:03 PM EDT
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

Pain Biomarker Study

NCT03511846
View directory record Official record
Conditions
Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Hemicrania Continua, Paroxysmal Hemicrania, SUNCT, Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and Tearing
Interventions
Oral capsaicin, Topical capsaicin, Intranasal capsaicin, Cold Water Irrigation, Medical Air, Low Flow Oxygen, High Flow Oxygen
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 25, 2026, 11:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Aspirin on Gut Microbiome

NCT02761486
View directory record Official record
Conditions
Healthy
Interventions
Aspirin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
50 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Jun 25, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

NCT02955758
View directory record Official record
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Interventions
Pembrolizumab
Biological
Lead sponsor
Joel Neal
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 25, 2026, 11:03 PM EDT
Active, not recruiting Not applicable Interventional

Integrative Medicine in Pain Management in Sickle Cell Disease

NCT05045820
View directory record Official record
Conditions
Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy
Interventions
needling acupuncture, laser acupuncture
Device
Lead sponsor
Indiana University
Other
Eligibility
14 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jun 25, 2026, 11:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Circulating Biomarkers in the Development of Type 1 Diabetes

NCT05505669
View directory record Official record
Conditions
Diabetes
Interventions
One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 25, 2026, 11:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Samples USOPTIVAL Study

NCT04792684
View directory record Official record
Conditions
Colorectal Cancer (CRC), Advanced Adenomas (AA)
Interventions
Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Diagnostic Test
Lead sponsor
Universal Diagnostics
Industry
Eligibility
45 Years to 84 Years
Enrollment
1,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
16
States / cities
Chula Vista, California • San Diego, California • Walnut Creek, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 25, 2026, 11:03 PM EDT
Completed No phase listed Observational

Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation

NCT02412579
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
None - Standard of Care
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Jun 25, 2026, 11:03 PM EDT
Recruiting No phase listed Observational

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

NCT04564989
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Head and Neck Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
3
States / cities
Rochester, Minnesota • Chapel Hill, North Carolina • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jun 25, 2026, 11:03 PM EDT
Recruiting Not applicable Interventional

Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0

NCT06725550
View directory record Official record
Conditions
Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy
Interventions
needling acupuncture, laser acupuncture
Device
Lead sponsor
Indiana University
Other
Eligibility
14 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jun 25, 2026, 11:03 PM EDT
Active, not recruiting No phase listed Observational

Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)

NCT02978118
View directory record Official record
Conditions
Carcinoma, Renal Cell, Carcinoma, Urothelial
Interventions
Immune cell and CTC detection procedures
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jun 25, 2026, 11:03 PM EDT
Recruiting No phase listed Observational

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

NCT05234177
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
20
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Bethesda, Maryland + 14 more
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jun 25, 2026, 11:03 PM EDT
Recruiting Phase 2 Interventional

Biomarkers to Detect Endocrine Therapy Resistance

NCT06067503
View directory record Official record
Conditions
Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
Interventions
18F-fluorofuranylnorprogesterone, Liquid Biopsy, Positron Emission Tomography/Computed Tomography
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 25, 2026, 11:03 PM EDT
Recruiting No phase listed Observational

Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

NCT06717243
View directory record Official record
Conditions
Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers, Immunotherapy
Interventions
Carboplatin/Cisplatin -Etoposide - Atezolizumab
Drug
Lead sponsor
Oncology Center of Biochemical Education And Research
Other
Eligibility
18 Years to 85 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jun 25, 2026, 11:03 PM EDT
Completed No phase listed Observational

Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)

NCT01173458
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Kansas City, Kansas • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Jun 25, 2026, 11:03 PM EDT
Recruiting Phase 2 Interventional

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

NCT06070012
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Tebentafusp
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 25, 2026, 11:03 PM EDT